Nektar Therapeutics
NKTR
199 hedge funds and large institutions have $1.78B invested in Nektar Therapeutics in 2016 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 101 increasing their positions, 34 reducing their positions, and 28 closing their positions.
197% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 34
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
25% more call options, than puts
Call options by funds: $8.72M | Put options by funds: $7M
6.33% more ownership
Funds ownership: 0% → 6.33% (+6.3%)
3% more funds holding
Funds holding: 194 → 199 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less capital invested
Capital invested by funds: $2.28B → $1.78B (-$503M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$38.9M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$38M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20.7M |
| 4 |
Primecap Management
Pasadena,
California
|
+$19.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$63M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$16.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.4M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$9.83M |
| 5 |
PC
PointState Capital
New York
|
-$9.45M |
NKTR Hedge Fund Activity: Q4 2016 in Review
199 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2016, worth a combined $1.78B — down 22% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new NKTR positions and 28 closed out — a net gain of 9 holders — while 101 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $38.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $63M sold.
- 199 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2016, up from 194 in Q3 2016.
- Funds reported $1.78B of Nektar Therapeutics stock for Q4 2016, down 22% quarter-over-quarter.
- 37 funds opened new Nektar Therapeutics positions in Q4 2016 and 28 closed out, a net change of +9 holders.
- The largest Nektar Therapeutics buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $38.9M added.
- The largest Nektar Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $63M sold.
Based on aggregated 13F filings for Q4 2016.